Compare Alcon AG (ALC) vs AXT Inc (AXTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs AXT Inc — how do they compare? Alcon AG trades at $74.32 (market cap $36.44B), while AXT Inc trades at $77.18 (market cap $4.83B). The key difference: Alcon AG is far larger — about 7.5× AXT Inc's market cap, and Alcon AG pays a 0.48% dividend while AXT Inc pays none. Which is the better fit depends on your goals.
| ALC | AXTI | |
|---|---|---|
Market Cap | $36.44B | $4.83B |
Sector | Health | Technology |
52-Week High | $90.12 | $140.83 |
52-Week Low | $62.02 | $2.05 |
Enterprise Value | $40.28B | $4.50B |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
AXTI trades at $78.47, up 6.31% on the day, with a bullish technical signal from moving averages and strong earnings beats in Q1 and Q2 2026. Revenue surged to $126 million in 2026 with a return to profitability, driven by record indium phosphide demand for AI data centers. The company secured a long-term supply agreement with Lumentum, accelerating capacity expansion.
Outlook is positive given AI-driven demand and analyst consensus, but high valuation ratios and operational cash flow deficits pose risks. The stock trades above the consensus price target of $72.50, suggesting near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →
